Loading…
Processa Pharmaceuticals, Inc. is projected to decline to $1.84 by 2027, a -14% move from its current price of $2.13. PCSA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.96 | $2.13 | $2.31 | 0.00% |
| Aug 6 | $1.90 | $2.13 | $2.39 | 0.00% |
| Aug 7 | $1.85 | $2.13 | $2.45 | 0.00% |
| Aug 8 | $1.81 | $2.13 | $2.51 | 0.00% |
| Aug 9 | $1.77 | $2.13 | $2.56 | 0.00% |
| Aug 10 | $1.74 | $2.13 | $2.60 | 0.00% |
| Aug 11 | $1.72 | $2.13 | $2.64 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.72 | $2.13 | $2.64 | 0.00% |
| Week 2 | $1.57 | $2.13 | $2.89 | 0.00% |
| Week 3 | $1.47 | $2.13 | $3.10 | 0.00% |
| Week 4 | $1.38 | $2.13 | $3.28 | -0.01% |
| Week 5 | $1.31 | $2.13 | $3.45 | -0.01% |
| Week 6 | $1.25 | $2.13 | $3.61 | -0.01% |
| Week 7 | $1.20 | $2.13 | $3.77 | -0.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on cancer therapies in the United States. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors.
NGC-Iri (PCS11T) is an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited.
Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Processa Pharmaceuticals, Inc. (PCSA) is a clinical-stage biopharmaceutical company whose current price is $2.03 per share. Its market capitalization is $5.62M, and it ranks 5253 by market cap.
The forecast landscape shows a mixed near-term path with potential longer-term upside. The 2030 forecast is an average of $2.35 with ROI 15.8 and the 2050 forecast is an average of $6.78 with ROI 234.
Investors should recognize the high risk and volatility reflected in the forecast, with years such as 2028 and 2029 showing softer averages before longer-term upside emerges.
A major floor 45.4% below — a decisive break under it would weaken the trend.
The nearest floor, 12.7% below — buyers have tended to step in here.
The nearest ceiling, 43.2% above — a clean break opens room to run.
A major ceiling 66.4% above — clearing it would confirm fresh momentum.
Key PCSA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PCSA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.37 | Sell | $2.28 | Sell |
| MA 10 | $2.43 | Sell | $2.34 | Sell |
| MA 20 | $2.28 | Sell | $2.31 | Sell |
| MA 50 | $2.29 | Sell | $2.35 | Sell |
| MA 100 | $2.53 | Sell | $2.65 | Sell |
| MA 200 | $3.75 | Sell | $4.57 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.00 | Neutral |
| Stoch RSI (14) | 10.48 | Buy |
| CCI (20) | -36.71 | Neutral |
| Williams %R (14) | -88.24 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -10.04 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 11.76 | Buy |
| TRIX (15) | 0.37 | Buy |
| Awesome (5,34) | 0.19 | Buy |
| Ultimate (7,14,28) | 45.48 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 2.11 | Buy |
| ADX (14) | 14.46 | Neutral |
| ATR (14) | 0.20 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 40, reinforcing a cautious near-term stance.
The trend indicators show SMA50 at $2.31 and SMA200 at $3.83, suggesting that near-term momentum could hover around the current price with resistance above the current level.
Support is indicated at $1.86 and resistance at $3.05, with a 30-day price range from $1.15 to $3.58. These levels frame a range within which the stock has traded over the past month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.85 | $2.13 | $2.44 | 0% | Neutral | |
| $1.34 | $1.84 | $2.72 | -14% | Neutral | |
| $1.14 | $1.66 | $2.62 | -22% | Bearish | |
| $1.30 | $2.00 | $3.33 | -6% | Neutral | |
| $1.56 | $2.51 | $4.35 | +18% | Neutral | |
| $1.64 | $2.76 | $4.95 | +30% | Bullish | |
| $1.67 | $2.93 | $5.42 | +38% | Bullish | |
| $1.47 | $2.68 | $5.10 | +26% | Bullish | |
| $1.30 | $2.47 | $4.81 | +16% | Neutral | |
| $1.19 | $2.35 | $4.68 | +10% | Neutral | |
| $1.84 | $4.10 | $8.98 | +92% | Bullish | |
| $3.34 | $7.43 | $17.09 | +249% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.85 | $2.13 | $2.53 | +0.00% |
| September 2026 | $1.72 | $2.09 | $2.65 | -1.92% |
| October 2026 | $1.73 | $2.13 | $2.76 | +1.93% |
| November 2026 | $1.58 | $1.97 | $2.59 | -7.45% |
| December 2026 | $1.45 | $1.83 | $2.44 | -7.26% |
Click any year to see its month-by-month PCSA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PCSA to range from $1.85 to $2.44 through 2026. The $2.13 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PCSA price prediction for 2027 points to an average of $1.84 (low $1.34, high $2.72) — a potential decline of -14% on today's $2.13. A consolidation phase looks the most probable path here.
In 2028, PCSA is projected to trade between $1.14 and $2.62, averaging $1.66 — a potential decline of -22% from today's $2.13. That is -10% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
Processa Pharmaceuticals, Inc.'s 2029 outlook centres on $2.00, within a $1.30 to $3.33 range. That is up +21% on the projected 2028 average. That marks a -6% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, PCSA could reach as high as $4.35, with a base case around $2.51 and support toward $1.56 — roughly +18% from $2.13. Price action looks broadly range-bound.
Expect PCSA to range from $1.64 to $4.95 through 2031. The $2.76 average target implies a +30% move from current prices. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The PCSA price prediction for 2032 points to an average of $2.93 (low $1.67, high $5.42) — a potential gain of +38% on today's $2.13. Momentum favours further upside here.
In 2033, PCSA is projected to trade between $1.47 and $5.10, averaging $2.68 — a potential gain of +26% from today's $2.13. That is -8% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Processa Pharmaceuticals, Inc.'s 2034 outlook centres on $2.47, within a $1.30 to $4.81 range. That is -8% versus the projected 2033 average. That marks a +16% change versus current levels. Price action looks broadly range-bound.
By 2035, PCSA could reach as high as $4.68, with a base case around $2.35 and support toward $1.19 — roughly +10% from $2.13. A consolidation phase looks the most probable path here.
Expect PCSA to range from $1.84 to $8.98 through 2040. The $4.10 average target implies a +92% move from current prices. That is up +74% on the projected 2035 average. Momentum favours further upside here.
The PCSA price prediction for 2050 points to an average of $7.43 (low $3.34, high $17.09) — a potential gain of +249% on today's $2.13. Buyers look set to stay in control over this stretch.
Investing $1,000 in PCSA today (≈ 469.483568 PCSA) could be worth
$3,489.22
+$2,489.22 (+249%) by 2050 · US Dollar
Based on the average projected PCSA price of $7.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PCSAwould be worth at today's price.
$1,000 invested in PCSA on Jul 31, 2025 (≈ 190.47619 PCSA) would be worth
$405.71
-$594.29 (-59.4%) today · 0.41× · US Dollar
Based on a PCSA entry price of $5.25 vs. today's $2.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.6 | $819.23 | -18.1% |
| 1 month ago | $1.96 | $1,086.73 | +8.7% |
| 3 months ago | $2.55 | $835.29 | -16.5% |
| 6 months ago | $2.63 | $811.43 | -18.9% |
| 1 year ago | $5.25 | $405.71 | -59.4% |
| All time (5.0y) ago | $3,100 | $0.69 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PCSA forecast.
Our base-case forecast reaches $4.30 around 2050.
Implied market cap at $4.30: $11.9M
The multi-year forecast points to a path of gradual expansion after a mixed near term. By 2026 the min, avg, and max are $1.85, $2.03, and $2.32 with ROI 0 and Neutral sentiment.
The 2030–2033 window shows modest to notable upside: 2030 min $1.46, avg $2.35, max $4.07 with ROI 15.8 and Neutral sentiment; 2031 min $1.51, avg $2.55, max $4.57 with ROI 25.6 and Bullish sentiment; 2032 min $1.57, avg $2.76, max $5.10 with ROI 35.8 and Bullish sentiment; 2033 min $1.37, avg $2.51, max $4.77 with ROI 23.6 and Bullish sentiment.
The outlook strengthens further into 2040 and 2050: 2040 min $1.69, avg $3.75, max $8.22 with ROI 84.6 and Bullish sentiment; and 2050 min $3.05, avg $6.78, max $15.59 with ROI 234 and Bullish sentiment. These figures illustrate potential long‑term upside amid shorter-term volatility.
Tap a question to reveal the answer.
2030 min $1.46, avg $2.35, max $4.07; ROI 15.8; sentiment Neutral.
The forecast shows upside in years such as 2031, 2032, 2040, and 2050 (e.g., 2031 avg $2.55; 2032 avg $2.76; 2040 avg $3.75; 2050 avg $6.78) but also bearish periods (e.g., 2028 avg $1.54; 2029 avg $1.87). These are estimates and carry significant risk and volatility.
2040 max $8.22, indicating a potential to approach that level per the forecast.
Current price $2.03; Market cap $5.62M.
2030 avg $2.35; 2040 avg $3.75; 2050 avg $6.78, with max values of $4.07 (2030), $8.22 (2040), and $15.59 (2050) and ROI figures of 15.8, 84.6, and 234 respectively; sentiment shifts from Neutral to Bullish by 2040 and 2050.
Processa Pharmaceuticals, Inc. Community Discussion
0Share your Processa Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.